research

LEMS: Firdapse Study Shows Encouraging Results

DMD: ReveraGen Drug Will Move to Human Testing

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

ALS: BrainStorm to Test NurOwn Cells in US

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1

Prosensa Will Pursue Accelerated Approval for Drisapersen to Treat DMD

SMA: ISIS-SMNRx Shows Benefit in Infants, Children

MD-CARE Act Congressional Briefing Accelerates Reauthorization Momentum

"The energy in the room was high, and the mood was optimistic," said Annie Kennedy, MDA's senior vice president of advocacy, speaking about the Congressional briefing on reauthorization of the MD-CARE Act that she attended and helped to organize. The briefing was co-hosted by MDA and other muscular dystrophy organizations in Washington, D.C., on Feb.

High-Calorie Diet May Help in ALS

A study supported in part by MDA has found that a high-calorie, high-carbohydrate diet is safe and well-tolerated in late-stage amyotrophic lateral sclerosis (ALS), that it leads to moderate weight gain, and that it may slow disease progression.

SMA: Interim Results Look Promising for SMN-Raising Drug

Interim results of a phase 2 clinical trial to test multiple doses of the experimental drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA) suggest that the drug is well-tolerated and may prolong ventilator-free survival.

MDA in Your Community


Grants